By Duke-NUS
This study, which appears in The New England Journal of Medicine, is the first to demonstrate cross-neutralizing reactivity in humans. The finding further boosts hopes of developing an effective and broad-spectrum next-generation vaccine against different coronaviruses.
Among the coronavirus family, one sub-group relies on the ACE2 molecule to enter human cells. Both SARS-CoV-1 and SARS-CoV-2 belong to this group as well as a number of coronaviruses circulating in animals such as bats, pangolins, and civets. While the exact route of transmission remains unknown, these viruses have the potential to jump from animals to humans and could start the next pandemic. Collectively, this group of viruses is called sarbecovirus.
“We explored the possibility of inducing pan-sarbecovirus neutralizing antibodies that can block the common human ACE2-virus interaction, which will be protective not only against all known and unknown SARS-CoV-2 VOCs, but also future sarbecoviruses,” says Chee Wah Tan, senior research fellow with the Duke-NUS Emerging Infectious Diseases (EID) program and co-first author of the study.
To test their hypothesis, researchers recruited eight people who recovered from SARS-CoV-1, which was responsible for the 2003 SARS epidemic, as well as 10 healthy people and 10 COVID-19 survivors. They then compared the immune response of the three groups before and after they were vaccinated with the SARS-CoV-2 vaccine.
In particular, they wanted to understand whether the neutralizing antibodies developed in the SARS-Vaccinated group could wipe out both SARS-CoV-1 and SARS-CoV-2 viruses as well as other sarbecoviruses, including potentially zoonotic sarbecoviruses that have been identified in bats and pangolins.
“Prior to vaccination, SARS-CoV-1 survivors had detectable neutralizing antibodies against SARS-CoV-1 but no or low-level anti-SARS-CoV-2 neutralizing antibodies. After receiving two doses of the mRNA vaccine, all displayed high levels of neutralizing antibodies against both SARS-CoV-1 and SARS-CoV-2,” says Wanni Chia, research fellow at the Duke-NUS EID program and co-first author of the study.
“Most importantly, they are the only group with a broad spectrum of neutralizing antibodies against 10 sarbecoviruses that were chosen to be examined.”
“Our study points to a novel strategy for the development of next-generation vaccines, which will not only help us control the current COVID-19 pandemic, but may also prevent or reduce the risk of future pandemics caused by related viruses,” says professor Wang Linfa from the Duke-NUS EID program, senior corresponding author of this study.
“As emerging variants of concern have already demonstrated some degree of immune evasion against the first-generation vaccines, this discovery has the potential to address that problem as the world continues COVID-19 vaccination to exit the pandemic. In addition, this can potentially act as a highly promising preventive vaccine against future coronavirus pandemics.”
The team is currently conducting a proof-of-concept study to develop a third-generation vaccine against different coronaviruses (3GCoVax) as well as broad neutralizing antibodies for therapy and is looking to recruit individuals who recovered from SARS infection in 2003. For those who would like to take part in ongoing studies, please contact [email protected].
Source: Duke-NUS
—
This post was previously published on futurity.org and is republished here under a Creative Commmons license.
***
You Might Also Like These From The Good Men Project
Compliments Men Want to Hear More Often 
Relationships Aren’t Easy, But They’re Worth It 
The One Thing Men Want More Than Sex 
..A Man’s Kiss Tells You Everything Join The Good Men Project as a Premium Member today.
All Premium Members get to view The Good Men Project with NO ADS.
A $50 annual membership gives you an all access pass. You can be a part of every call, group, class and community.
A $25 annual membership gives you access to one class, one Social Interest group and our online communities.
A $12 annual membership gives you access to our Friday calls with the publisher, our online community.
Register New Account
Log in if you wish to renew an existing subscription.
Username
First Name
Last Name
Password
Password Again
Choose your subscription level
- Yearly - $50.00 - 1 Year
- Monthly - $6.99 - 1 Month
Credit / Debit Card PayPal Choose Your Payment Method
Auto Renew
Subscribe to The Good Men Project Daily Newsletter By completing this registration form, you are also agreeing to our Terms of Service which can be found here.Need more info? A complete list of benefits is here.
—
Photo credit: Towfiqu barbhuiya on Unsplash
The post Sars Survival and Pfizer Vax Combine for Useful Antibodies appeared first on The Good Men Project.
Original Article
